ClinicalTrials.gov
ClinicalTrials.gov Menu

Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00098189
Recruitment Status : Completed
First Posted : December 6, 2004
Last Update Posted : August 31, 2006
Sponsor:
Information provided by:
Novartis

Brief Summary:
This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.

Condition or disease
Psoriasis

Study Type : Observational
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
Study Start Date : July 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consenting patients who participated in the core clinical trial

ClinicalTrials.gov Identifier: NCT00098189     History of Changes
Other Study ID Numbers: Ext. 1 to ASM981C201
First Posted: December 6, 2004    Key Record Dates
Last Update Posted: August 31, 2006
Last Verified: August 2006

Keywords provided by Novartis:
Safety, psoriasis, adverse event, SAE, extension

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Pimecrolimus
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action